查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363172

泌尿生殖治疗药物的市场规模、份额和趋势分析报告：按适应症、按产品、地区、细分趋势，2023-2030

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

泌尿生殖医学市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，预计2023年至2030年全球泌尿生殖药物市场规模将以1.1%的年复合成长率增长，到2030年将达到317.5亿美元。

该领域预计将受到大公司大量研发投资的推动，并导致候选药物的大规模开发。因此，预计为泌尿生殖疾病提供有效治疗选择的泌尿生殖药物市场的药物数量将迅速增加。

此外，不断增加的药物召回也加剧了临床上迫切需要开发具有标靶治疗机制的相对较新和先进的药物。总的来说，这些要素在预测期内为该行业提供了巨大的成长机会。

此外，主要市场参与者在全球的影响力不断扩大，预计将提高患者和医生对泌尿生殖系统疾病治疗方案的意识层级。预计这将在预测期内进一步扩大泌尿生殖市场的成长潜力。由于仿製药竞争加剧、假药数量增加以及多项专利即将到期，预计未来年度市场成长将放缓。

泌尿生殖治疗市场报告亮点

  • 由于全球罹患率上升，2022年前列腺癌在适应症领域中占据最大份额。据估计，蛋白质体学技术的进步以及筛检和诊断方法的改进是这种压倒性市场份额的背后原因。
  • 2022年，北美将以超过37.0%的份额主导全球泌尿生殖医学市场。这一主导份额是由于该地区的高疾病负担，预计这将鼓励研究人员和医疗保健专业人员倾向于先进的配方技术，扩大该领域的成长范围。
  • 预计亚太地区的年复合成长率在预测期内将超过 4.8%。这种快速增长归因于医疗保健支出的增加以及主要行业参与者为提高临床研究和製造设施的基础设施品质配合措施。
  • 市场参与企业正在透过新产品开拓和合作策略扩大市场占有率并提高在该领域的影响力。例如，2023年3月，诺华公司透过与Aduro Biotech合作，进一步加强了其癌症免疫疗法研究计划，增加了发现和开发下一代癌症免疫疗法的力度。

目录

第1章调查方法与范围

第2章执行摘要

第3章泌尿生殖药物市场的变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 泌尿生殖医学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章泌尿生殖医学市场：按适应症估计与趋势分析

  • 泌尿生殖医学市场：重点
  • 泌尿生殖药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 摄护腺癌
  • 卵巢癌
  • 膀胱癌
  • 子宫颈癌
  • 肾癌
  • 勃起功能障碍
  • 尿道感染
  • 尿失禁和膀胱过动症
  • 性行为感染传染病
  • 间质性膀胱炎
  • 血尿
  • 良性摄护腺增生症

第5章泌尿生殖医学市场：按产品估价及趋势分析

  • 泌尿生殖医学市场：重点
  • 泌尿生殖药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 泌尿系统
  • 荷尔蒙治疗
  • 妇科
  • 感染疾病
  • 其他的

第6章泌尿生殖医学市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的泌尿生殖药物市场：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Abbott
    • Bristol-Myers Squibb Co.
    • Novartis AG
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Ionis Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Pfizer, Inc.
    • AstraZeneca
    • GlaxoSmithKline
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Allergan.
    • Antares Pharma
Product Code: GVR-1-68038-285-3

Genitourinary Drugs Market Growth & Trends:

The global genitourinary drugs market size is expected to reach USD 31.75 billion by 2030, expanding at a CAGR of 1.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

Genitourinary Drugs Market Report Highlights:

  • Prostate cancer held the largest share of the indication segment in 2022 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share.
  • In 2022, North America dominated the global genitourinary drugs vertical with a share of over 37.0%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector
  • Asia Pacific is expected to witness a lucrative CAGR of over 4.8% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players
  • The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2023, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Indication
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Genitourinary Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Genitourinary Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Genitourinary Drugs Market: Indication Estimates & Trend Analysis

  • 4.1. Genitourinary Drugs Market: Key Takeaways
  • 4.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Prostate Cancer
    • 4.3.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Ovarian Cancer
    • 4.4.1. Ovarian cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Bladder Cancer
    • 4.5.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Cervical Cancer
    • 4.6.1. Cervical cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Renal Cancer
    • 4.7.1. Renal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Erectile Dysfunction
    • 4.8.1. Erectile dysfunction market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Urinary Tract Infections
    • 4.9.1. Urinary tract infections market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Urinary Incontinence & Overactive Bladder
    • 4.10.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.11. Sexually Transmitted Diseases
    • 4.11.1. Sexually transmitted diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.12. Interstitial Cystitis
    • 4.12.1. Interstitial cystitis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.13. Hematuria
    • 4.13.1. Hematuria market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.14. Benign Prostatic Hyperplasia
    • 4.14.1. Benign prostatic hyperplasia market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Genitourinary Drugs Market: Product Estimates & Trend Analysis

  • 5.1. Genitourinary Drugs Market: Key Takeaways
  • 5.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Urologicals
    • 5.3.1. Urologicals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Hormonal Therapy
    • 5.4.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Gynecological
    • 5.5.1. Gynecological market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Anti-infectives
    • 5.6.1. Anti-infectives market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Genitourinary Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Genitourinary Drugs Market by Region: Key Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Abbott
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Bristol-Myers Squibb Co.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Genentech, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. F. Hoffmann-La Roche Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Ionis Pharmaceuticals, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Eli Lilly and Company
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Merck & Co. Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Pfizer, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AstraZeneca
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. GlaxoSmithKline
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Teva Pharmaceutical Industries Ltd.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Bayer AG
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Allergan.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Antares Pharma
      • 7.2.15.1. Company Overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 3 North America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Europe genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Germany genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 15 UK genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 France genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 17 France genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Italy genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Spain genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Sweden genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Norway genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Denmark genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 32 China genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Japan genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 35 India genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Thailand genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 42 South Korea genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Brazil genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Mexico genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Argentina genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 56 South Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 60 UAE genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Kuwait genitourinary drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Genitourinary drugs: market outlook
  • Fig. 9 Genitourinary Drugs Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Genitourinary drugs market driver impact
  • Fig. 15 Genitourinary drugs market restraint impact
  • Fig. 16 Genitourinary drugs market strategic initiatives analysis
  • Fig. 17 Genitourinary drugs market: Indication movement analysis
  • Fig. 18 Genitourinary drugs market: Indication outlook and key takeaways
  • Fig. 19 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Ovarian cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Bladder cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cervical cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Renal cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Erectile dysfunction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Urinary tract infections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Urinary incontinence & overactive bladder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Sexually transmitted diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Interstitial cystitis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Hematuria market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Benign prostatic hyperplasia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Genitourinary drugs market: Product movement analysis
  • Fig. 32 Genitourinary drugs market: Product outlook and key takeaways
  • Fig. 33 Urologicals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Gynecological market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Anti-infectives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Global genitourinary drugs market: Regional movement analysis
  • Fig. 39 Global genitourinary drugs market: Regional outlook and key takeaways
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)